The U.S. Food and Drug Administration (FDA) previously granted orphan drug designation to deucrictibant for the treatment of bradykinin-mediated angioedema in March 2022.

Patients with hereditary angioedema whose attacks impacted their larynx experienced on-demand relief within 1.29 hours with ...

Find out how Sung Jinwoo saves and brings back Cha Hae-In from the brink of death on Jeju Island in the Solo Leveling anime ...

The webinar, held on March 25, 2025, featured key opinion leaders (KOLs) and outlined the progress of sebetralstat, an oral plasma kallikrein inhibitor developed for on-demand treatment of hereditary ...

The changing therapeutic landscape for urticaria, angioedema, and anaphylaxis is evidenced by emerging treatments reported at ...

New data presented at the AAAAI/WAO 2025 Joint Congress highlighted sebetralstat’s promise in reducing the time to relief for HAE attacks, with a median time of 11.5 minutes from attack onset to ...

During the episode of MBC's 'How Do You Play?' airing on March 22, a '2025 version of surprise attack' by Yoo Jae-suk will ...

New data presented at the AAAAI/WAO 2025 Joint Congress highlighted sebetralstat’s promise in reducing the time to relief for HAE attacks, with a median time of 11.5 minutes from attack onset to ...

Higher levels of bradykinin mean more inflammation and leaky blood vessel walls, which cause swelling attacks. The main symptom of HAE is swelling in different parts of the body. This is from a ...

The primary endpoint is time-normalized monthly HAE attacks at 6 months, and a key secondary endpoint includes the proportion of participants who are attack-free at 6 months. After 6 months ...

KalVista Pharmaceuticals has finished enrolling subjects in its KONFIDENT-KID trial of sebetralstat for hereditary angioedema ...